Association between statin use and Alzheimer's disease with dose response relationship

This study aimed to determine the dose-response relationship between the levels of statin exposure and the incidence of Alzheimer's disease (AD). We included 119,013 Korean adults (>= 60 years old) using a database from the Korean National Health Insurance Service (2002-2013). Statin exposure was treated as a time-varying variable. Incidence of AD was defined by the first claim code for AD with anti-Alzheimer drugs. AD occurred in 9467 cases during a median 7.2 years of follow-up. Overall, statin use was not associated with an increased risk of AD incidence [adjusted hazard ratio (aHR)=1.04; 95% confidence interval (CI)=0.99-1.10]. When examined by level of statin exposure, statin prescription<540 days during a 2-year window time was associated with a higher risk for incidence of AD compared to statin non-use. However, days of prescription540 and cumulative defined daily dose >= 540 of statin were associated with decreased risk of AD [aHR (95% CI)=0.87 (0.80-0.95) and 0.79 (0.68-0.92), respectively]. Our findings indicate that less persistent statin use is associated with increased risk of AD, whereas persistent and adherent statin use is associated with decreased risk of AD.

Automated summary

The study found that statin use was not associated with an increased risk of Alzheimer's disease incidence overall. However, statin prescription of less than 540 days within a 2-year window time was associated with a higher risk of AD, while days of prescription 540 and cumulative defined daily dose >= 540 were associated with a decreased risk of AD. This suggests that less persistent statin use is linked to an increased risk of AD, while persistent and adherent use of statin is associated with a decreased risk of AD.